|Values are valid only on day of printing.|
Monitoring antibody levels during pregnancy to help assess the risk of hemolytic disease of the newborn
|Test ID||Reporting Name||Available Separately||Always Performed|
|ABID2||Antibody Identification, RBC||Yes||No|
|DCTM||Direct Coombs, B||Yes||No|
|MDCC3||Monospecific Direct Coombs C3, B||Yes||No|
|MDCG||Monospecific Direct Coombs IgG, B||Yes||No|
|SPAG||Special Red Cell Ag Typing||Yes||No|
The initial test performed is an antibody identification. If the antibody problem identified is not relevant in hemolytic disease of the newborn, or if titrations are not helpful, the titer will be cancelled and will be replaced by the antibody identification test. Depending upon the antibody identification results, additional tests, ie, monospecific direct Coombs, antibody elution, antibody absorption, and red cell antigen typing may be added and charged. A consultation service is offered, at no charge, regarding the clinical relevance of red cell antibodies.
ABID2: Ten-Cell Panel
ABAB, SPAG: Standard Blood Bank Techniques
ABEL: Acid-EDTA Elution/Other standard methods may be used in difficult cases.
DCTM, MDCG, MDCC3: Direct Antiglobulin Test